Related Experiment Videos
Parallel solid-phase synthesis of vitronectin receptor (alphavbeta3) inhibitors.
A Gopalsamy1, H Yang, J W Ellingboe
1Wyeth-Ayerst Research, Pearl River, NY 10965, USA. gopalsa@war.wyeth.com
Bioorganic & Medicinal Chemistry Letters
|August 11, 2000
Summary
Researchers rapidly optimized an alphavbeta3 inhibitor lead using solid-phase synthesis. This approach enabled efficient exploration of structure-activity relationships for drug discovery.
Area of Science:
- Medicinal Chemistry
- Organic Synthesis
- Drug Discovery
Background:
- The vitronectin receptor (alphavbeta3) is a key target in diseases like cancer and osteoporosis.
- Developing potent and selective inhibitors is crucial for therapeutic intervention.
Purpose of the Study:
- To rapidly optimize a lead compound targeting the vitronectin receptor (alphavbeta3).
- To explore the structure-activity relationship (SAR) of novel inhibitors.
Main Methods:
- Utilized a combinatorial approach employing solid-phase synthesis.
- Employed orthogonally bis protected 2,3-diaminopropionic acid for C-terminus immobilization.
- Performed selective deprotection, alpha-amino group functionalization, acyl resorcinol scaffold attachment, and N-terminus diversification.
Main Results:
- Successfully generated a library of potential alphavbeta3 inhibitors.
- Established a rapid and efficient method for lead optimization.
- Identified key structural modifications influencing inhibitory activity.
Conclusions:
- The combinatorial solid-phase synthesis strategy is effective for rapid optimization of alphavbeta3 inhibitors.
- This methodology facilitates efficient SAR exploration, accelerating drug discovery efforts.